CN104288163B - Application of L-arabinose to preparation of medicine or health care products for preventing or curing hyperammonemia - Google Patents
Application of L-arabinose to preparation of medicine or health care products for preventing or curing hyperammonemia Download PDFInfo
- Publication number
- CN104288163B CN104288163B CN201410611800.7A CN201410611800A CN104288163B CN 104288163 B CN104288163 B CN 104288163B CN 201410611800 A CN201410611800 A CN 201410611800A CN 104288163 B CN104288163 B CN 104288163B
- Authority
- CN
- China
- Prior art keywords
- arabinose
- application
- group
- medicine
- blood ammonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses the application of L-arabinose to the preparation of medicine or health care products for preventing or curing hyperammonemia, and particularly discloses the application of L-arabinose to the preparation of medicine or health care products for reducing blood ammonia and/or endotoxin. The applicant finds, in experiments, that L-arabinose can effectively reduce the level of blood ammonia and endotoxin of a mouse (1 to 4 grams/kg/day), and body health is not damaged while the function is achieved.
Description
Technical field
The present invention relates to the purposes of L-arabinose, and in particular to L-arabinose is preparing prevention or treating hyperammonemia
Medicine or health products in application.
Background technology
Hyperammonemia be due to internal urea cycle disorder, cause vivo acid decompose and produce ammonia and by intestines inhale
The ammonia of receipts, it is impossible to which smoothly urea synthesis are excreted, causes free ammonia to be accumulated in vivo, forms hyperammonemia.Internal mistake
The ammonia of amount has neurotoxicity, with the characteristics of central nervous system function imbalance and metabolic disorder, with hypophrenia, consciousness barrier
Hinder, nervous system signs show for Major Clinical.Hyperammonemia great majority are caused by hepatic disorder.Hepatic encephalopathy is severe liver disease
Cause based on metabolic disorder, with consciousness changing and stupor for the central nervous system function disorder of main performance synthesis
Illness.At present, ammonia poisoning theory is still acknowledged as the Central Position of the numerous pathogenesis hypothesis of hepatic encephalopathy, and hepatic encephalopathy is controlled
Treat still based on reduce blood ammonia, the method for most common of which is：Oral lactulose.
L-arabinose is a kind of aldopentose, the monose containing 5 carbon atoms and with aldehyde radical, the content in plant
It is only second to D- wood sugars.Existing research shows, L-arabinose has fat-reducing, lipid-loweringing, hypoglycemic, relaxes bowel and other effects；But mesh
It is front not yet to find to be used for L-arabinose to prevent or treat the relevant report of hyperammonemia.
The content of the invention
The technical problem to be solved in the present invention is to provide L-arabinose and is preparing prevention or treating the medicine of hyperammonemia
Or the application in health products.
The technical scheme is that：L-arabinose is in the medicine or health products for preparing prevention or treating hyperammonemia
Application.
Specifically, the present invention provides application of the L-arabinose in the medicine or health products that reduce blood ammonia is prepared, this
It is bright L-arabinose is also provided to reduce endotoxic medicine or the application in health products preparing, the present invention further provides L- Ah
Uncle's sugar is drawn simultaneously to reduce blood ammonia and endotoxic medicine or the application in health products in preparation.
Specifically application process is：L-arabinose is taken, pharmaceutic adjuvant is added or be added without, is prepared into according to a conventional method each
Pharmaceutical preparation is planted, the existing regular dosage form such as capsule, tablet or granule can be specifically made.Or take L-arabinose,
Add or be added without auxiliary material, health products are prepared into according to a conventional method.
Applicant has found that in an experiment L-arabinose can effectively reduce the blood ammonia and endogenous toxic material of mouse (1～4 gram/kg/ days)
Plain level, and while above-mentioned functions are reached, do not damage body health.
Specific embodiment
The reduce blood ammonia of L-arabinose, endotoxic effect are further illustrated below by experiment.
First, L-arabinose is to CCl4Cause the impact of hepatic injury mouse blood ammonia
1. experiment material and method
1.1 medicines and reagent
L-arabinose (purity 99%):Thomson Biotech (Xiamen) Corporation, lot number：1009081；Lactulose mouth
Take solution (66.7%)：Beijing Hanmei Medicine Co., Ltd, lot number：130457；Biological mistake is built up in kit of blood ammonia determination, Nanjing
Journey research institute；Chromogenic substrate tachypleus amebocyte lysate box (quantitative measurement of endotoxin detection), Xiamen BioEndo Technology ， Co.Ltd；Remaining reagent
It is domestic pure analysis pure.
1.2 instrument
TGL-16R type high speed freezing centrifuge Hema Medical Instrument Co., Ltds；RT-9100 type semi-automatic biochemical analyzers Shenzhen thunder Du
Life science limited company；Electronic balance, Mettler-Toledo Instrument Shanghai Inc..
1.3 animal used as test
Kunming mice, SPF levels, body weight 18-22g is provided by Hunan SJA Laboratory Animal Co. ， Ltd.Production is permitted
Can the number of card：SCXK (Hunan) 2009-0004.
The foundation and administration of 1.4 hyperammonemia animal models
Kunming mice 72 is taken, 6 groups are randomly divided into：Blank group, model group, positive group (lactulose group), L-arabinose
Low dose group, L-arabinose middle dose group, L-arabinose high dose group.In addition to control group injection peanut oil, remaining each group
Mouse pressed 5%CCl per three days4Oil solution lumbar injection, dosage 0.1ml/10g, continuous injection 48 days.L-arabinose is low, in,
High dose group mouse presses 1g/kg, 2g/kg, 4g/kg gastric infusion；Positive group gives lactulose 6g/kg；Control group and model group
The distilled water of mouse stomach equivalent, once a day, continuous 48 days.
The measure of 1.5 blood ammonias and endotoxin content
49th day, water was can't help in mouse fasting, is weighed, and eyeball takes blood, separated serum.The measure of blood ammonia and endotoxin content is pressed
Kit explanation is operated.
1.6 statistical method
Data analysis is carried out using the statistical softwares of SPSS 13.0, experimental data withRepresent, two independent samples are equal
Number compares to be checked using t, comparing two-by-two between multiple samples adopts one-way analysis of variance, and P ＜ 0.05 are with statistics
Meaning.
2. result
Impact of 2.1 L-arabinoses to mouse blood ammonia：
Impact result of the L-arabinose to mouse blood ammonia is as described in Table 1.From table 1 it follows that continuously giving
After medicine 48 days, compare with normal group, model group blood ammonia is raised, statistically significant；Compare with model group, lactulose group blood ammonia drop
It is low, it is statistically significant；Compare with model group, L-arabinose each group blood ammonia is reduced, wherein middle and high dosage group has statistics to anticipate
Justice, low dose group is not statistically significant；Compare with lactulose group, the middle and high dosage group blood ammonia of L-arabinose is reduced, and has statistics
Learn meaning；Thus illustrate, in CCl4In causing hepatic injury mouse hyperammonemia model, L-arabinose has obvious reduce blood ammonia to act on,
It is better than positive drug lactulose by can be seen that its effect in data.
Table 1：Impact of the L-arabinose to mouse blood ammonia (N=12)
Note：Compare with Normal group, * p<0.05, * * p<0.01；Compare with model group,#P ＜ 0.05,##P ＜ 0.01；
Compare with lactulose group,▲P ＜ 0.05,▲▲P ＜ 0.01.
Impact of 2.2 L-arabinoses to Mouse endotoxin：
Impact result of the L-arabinose to Mouse endotoxin is as described in Table 2.From Table 2, it can be seen that continuous
After administration 47 days, compare with normal group, model group endotoxin is raised, statistically significant；Compare with model group, in lactulose group
Toxin is in a slight decrease, is not statistically significant；Compare with model group, L-arabinose each group endotoxin is reduced, and has statistics
Meaning；Compare with lactulose group, L-arabinose each group endotoxin is reduced, all statistically significant.Thus illustrate, L- is Arabic
Sugar has obvious reduce endotoxin to act on, and reduce blood ammonia positive drug lactulose is acted on without reduce endotoxin.
Table 2：Impact of the L-arabinose to Mouse endotoxin (N=12)
Note：Compare with Normal group, * p<0.05, * * p<0.01；Compare with model group,#P ＜ 0.05,##P ＜ 0.01；
Compare with lactulose group,▲P ＜ 0.05,▲▲P ＜ 0.01.
2nd, L-arabinose causes blood ammonia to raise the impact of mouse blood ammonia ammonium chloride
1. experiment material and method
1.1 medicines and reagent
L-arabinose (purity 99%):Thomson Biotech (Xiamen) Corporation, lot number：1009081；Lactulose mouth
Take solution (66.7%)：Beijing Hanmei Medicine Co., Ltd, lot number：130457；Biological mistake is built up in kit of blood ammonia determination, Nanjing
Journey research institute；Remaining reagent is domestic pure analysis pure.
1.2 instrument
TGL-16R type high speed freezing centrifuge Hema Medical Instrument Co., Ltds；RT-9100 type semi-automatic biochemical analyzers Shenzhen thunder Du
Life science limited company；Electronic balance, Mettler-Toledo Instrument Shanghai Inc..
1.3 animal used as test
Kunming mice, SPF levels, body weight 18-22g is provided by Hunan SJA Laboratory Animal Co. ， Ltd.Production is permitted
Can the number of card：SCXK (Hunan) 2009-0004.
The foundation and administration of 1.4 hyperammonemia animal models
Kunming mice 72 is taken, 6 groups are randomly divided into：Blank group, model group, positive group (lactulose group), L-arabinose
Low dose group, L-arabinose middle dose group, L-arabinose high dose group.In addition to control group injecting normal saline, remaining is each
Group mouse presses daily 5% ammonium chloride physiological saline lumbar injection, dosage 0.1ml/10g, continuous injection 28 days.L-arabinose
Basic, normal, high dosage group mouse presses 1g/kg, 2g/kg, 4g/kg gastric infusion；Positive group gives lactulose 6g/kg；Control group and
The distilled water of model group mouse stomach equivalent, once a day, continuous 28 days.
The measure of 1.5 Blood Ammonia Concentrations
29th day, water was can't help in mouse fasting, is weighed, and eyeball takes blood, separated serum.The measure of Blood Ammonia Concentration is said by kit
It is bright to be operated.
1.6 statistical method
Data analysis is carried out using the statistical softwares of SPSS 13.0, experimental data withRepresent, two independent samples are equal
Number compares to be checked using t, comparing two-by-two between multiple samples adopts one-way analysis of variance, and P ＜ 0.05 are with statistics
Meaning.
2. result
Impact of 2.1 L-arabinoses to mouse blood ammonia：
Impact result of the L-arabinose to mouse blood ammonia is as described in Table 3.From table 3 it is observed that continuously giving
After medicine 28 days, compare with normal group, model group blood ammonia is raised, statistically significant；Compare with model group, lactulose group blood ammonia drop
It is low, it is statistically significant；Compare with model group, L-arabinose each group blood ammonia is reduced, and wherein high dose group is statistically significant,
Low, middle dose group is not statistically significant.Thus illustrate, in ammonium chloride causes mouse hyperammonemia model, L-arabinose has bright
Aobvious reduce blood ammonia effect, is acted on by can be seen that wherein high dose group (4g/kg) in data with positive drug lactulose (6g/kg)
Quite.
Table 3：Impact of the L-arabinose to mouse blood ammonia (N=12)
Note：Compare with Normal group, * p<0.05, * * p<0.01；Compare with model group,#P ＜ 0.05,##P ＜ 0.01；
Compare with lactulose group,▲P ＜ 0.05,▲▲P ＜ 0.01.
Claims (6)
- Application of the 1.L- arabinoses in the medicine or health products for preparing prevention or treating hyperammonemia.
- 2. application according to claim 1, it is characterised in that：Its application is realized by reducing blood ammonia.
- 3. application according to claim 1, it is characterised in that：Its application is realized by reducing endotoxin.
- 4. application according to claim 1, it is characterised in that：Its application is by reducing blood ammonia and endotoxin simultaneously come real Existing.
- 5. the application according to any one of Claims 1 to 4, it is characterised in that：L-arabinose is taken, is added or is added without Pharmaceutic adjuvant, is prepared into according to a conventional method various pharmaceutical preparations.
- 6. the application according to any one of Claims 1 to 4, it is characterised in that：L-arabinose is taken, is added or is added without Auxiliary material, is prepared into according to a conventional method health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410611800.7A CN104288163B (en) | 2014-11-04 | 2014-11-04 | Application of L-arabinose to preparation of medicine or health care products for preventing or curing hyperammonemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410611800.7A CN104288163B (en) | 2014-11-04 | 2014-11-04 | Application of L-arabinose to preparation of medicine or health care products for preventing or curing hyperammonemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104288163A CN104288163A (en) | 2015-01-21 |
| CN104288163B true CN104288163B (en) | 2017-05-10 |
Family
ID=52308278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410611800.7A Active CN104288163B (en) | 2014-11-04 | 2014-11-04 | Application of L-arabinose to preparation of medicine or health care products for preventing or curing hyperammonemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104288163B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103156865B (en) * | 2013-03-14 | 2015-12-23 | 广西壮族自治区中国科学院广西植物研究所 | L-arabinose is preparing the application in medicine or health product |
| CN103478738B (en) * | 2013-09-17 | 2016-02-10 | 深圳太太药业有限公司 | A kind of composition with fat-reducing body shaping and Weight management effect |
-
2014
- 2014-11-04 CN CN201410611800.7A patent/CN104288163B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| L—阿拉伯糖在各种饮料中的健康功能;山东福田科技集团市场研究中心;《中国食品报第008版》;20111207;第1-2页 * |
| 低聚糖的生理功能及在食品中的应用;李文芹等;《中国食品添加剂》;20081231(第2期);第69-72页 * |
| 内毒素诱发肝硬化大鼠发生肝性脑病的实验研究;李夏青等;《中国病理生理杂志》;19991231;第15卷(第2期);第151-153页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104288163A (en) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101343819B1 (en) | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN114209739A (en) | Application of pulsatilla chinensis extract in preparation of antidepressant drug | |
| CN104288163B (en) | Application of L-arabinose to preparation of medicine or health care products for preventing or curing hyperammonemia | |
| CN103181940B (en) | Liver protection tablet with delicious taste used for pets | |
| Zhang et al. | Intestinal microbiology and metabolomics of streptozotocin-induced type 2 diabetes mice by polysaccharide from Cardamine violifolia | |
| CN102224924A (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN103721130B (en) | A kind of Chinese medicine composition for treating gout anti-trioxypurine | |
| CN101085037B (en) | Traditional Chinese medicine preparation for animals and preparation method thereof | |
| CN107496438B (en) | Application of Phellinus linteus polysaccharide in preparing medicine and health food | |
| CN108186631A (en) | A kind of pharmaceutical composition and its preparation method and application | |
| CN109620857B (en) | Peanut coat active component and application thereof in preparation of anti-obesity and anti-diabetic drugs | |
| CN104173363B (en) | Application of adenosine compound in preparation of medicine for preventing and treating stress disorder | |
| CN108379252B (en) | Gooseberry anthocyanidin is preparing the application in anti-hepatic fibrosis drug or health care product | |
| WO2011013999A2 (en) | Composition containing chitooligosaccharide for recovering from fatigue | |
| CN106074643B (en) | Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food | |
| CN102525885A (en) | Ketoconazole gel and preparation method thereof | |
| CN104666319B (en) | Rhodioside is preparing the application in treating gout medicine | |
| Choi et al. | Protective effect of heat-processed ginseng (sun ginseng) in the adenine-induced renal failure rats | |
| CN101143203A (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN109200084A (en) | Rosewood leaf extract and its application | |
| CN100551357C (en) | The application of prepared from coriolus versicolor mycelium in preparation resisting fatigue medicament | |
| Galland | Lifestyle Influences on the Microbiome | |
| CN105997983B (en) | Application of the 5 hydroxymethyl furfural in preparing Anti-helicobacter pylori drugs | |
| RU2716223C2 (en) | Composition in form of syrup for body detoxication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Ziming Inventor after: Li Dianpeng Inventor after: Zhang Li Inventor after: Liu Jinlei Inventor after: Chen Yueyuan Inventor before: Yang Ziming |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YANG ZIMING TO: YANG ZIMING LI DIANPENG ZHANG LI LIU JINLEI CHEN YUEYUAN |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190220 Address after: 361026 No. 10 Xinyuan South Road, Xinyang Street, Haicang District, Xiamen City, Fujian Province Patentee after: Thomson Biotech (Xiamen) Co., Ltd. Address before: No. 85 Yanshan Street, Yanshan District, Guilin City, Guangxi Zhuang Autonomous Region Patentee before: Guangxi Institute of Botany, Chinese Academy of Sciences |